Friday, October 28, 2005

Psoriasis And The Social Connection

People with psoriasis perceive they have less social support, have difficulty expressing their feelings and have more trouble with social relationships than others, a new study shows.
Newswise — The study says these life stresses may make them more prone to outbreaks of their psoriasis.
Researchers led by Angelo Picardi, M.D., suggest in the November-December issue of Psychomatics that “psychological interventions aimed at increasing emotional awareness, fostering the security felt in close interpersonal relationships and increasing social support might help reduce” outbreaks or at least lessen their severity.
The scientists from La Sapienza University in Rome studied 33 patients with psoriasis who had a recent worsening of their symptoms and 73 patients who had other minor skin conditions. Both groups were asked about stressful events over the past year, specifically about their social and emotional lives.
Psoriasis is an inflammatory skin condition that affects about 7 million Americans. The study participants had plaque psoriasis, the most common form, which appears as patches of raised, reddish skin covered by silvery-white scales and forms most commonly on the elbows, knees and lower back.
The researchers found that, in comparison with the group that had minor conditions, the patients with a recent psoriasis outbreak had lower perceived social support, more characteristics of bottled-up emotions and higher “attachment-related anxiety.” There were no differences in their scores, however, on measures that tested experiences in close relationships.
People who are high in attachment-related anxiety tend to worry about whether their partners really love them and often fear rejection. In addition, some people are more avoidant that others. People who are high in attachment-related avoidance are less comfortable depending on and opening up to others and are reluctant to ask their partners for comfort or support.
Age, gender, education, marital status and alcohol consumption were taken into consideration when assessing patient outcomes.
“Theoretical models emphasize that these persons tend to rely more on cognition and cognitive information than on feelings and emotional information,” Picardi said. “Clearly, self-regulation is compromised both internally and externally, which may increase susceptibility to disease.
“Perceived social support is a subjective measure, but when the level is higher, it is associated with better health,” Picardi added. “Immunological processes play a major role in the pathophysiology of psoriasis.” He said that prior research has shown that stress has particular effects on the skin, including slower wound healing, greater susceptibility of skin cells and a higher propensity for inflammation.
Picardi A, et al. Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychomatics 46(6), 2005.

Monday, October 24, 2005

Living With Psoriasis

"People judge us on the basis of our skin — our whole culture is based on cosmetics, lotions, creams and all that," said Finkelstein, of Oakland, Calif. "With (psoriasis), there's a whole layer of psychosocial problems, feelings of embarrassment, of shame, of ultimately feeling isolated."
But these days, Finkelstein, a filmmaker, has cast off the shy persona and is sharing his story with a new documentary, "My Skin's on Fire: Living With Psoriasis." DVDs of the film can be ordered for free at www.beyondpsoriasis.com.
He said now is an ideal time to shed light on the skin disease that affects more than 5 million people because, thanks to new medications, it's no longer a disease that needs to remain hopelessly hidden.
Rather than treating the disease topically, a new class of drugs known as "biologics" and "immuno-supressants" target the internal cause — an immune system on overdrive, which leads to the visible pile-up of inflamed skin cells. Inflammation normally protects the body, but too much of it is harmful.
"Here, really in the last 2 to 3 years, they've changed the disease of psoriasis. For many years it was considered an inflammatory skin disease. Now it's known as an 'immune-mediated disease,'" he says. "They've been able to pinpoint some of the mechanisms that misfire in the immune system."
But as Finkelstein's film shows, living with psoriasis is often far more than just a bothersome condition. Its obvious symptoms — flaky, red skin — can be a tremendous mental burden as well.
In the film, Finkelstein follows the typical trajectory of dealing with psoriasis. First, small patches of flaky skin crop up, usually when a person is a young adult. Then comes the diagnosis of psoriasis. The person may feel confused, wondering where they got such a disease, but a bit of questioning often reveals that it runs in the family — a trait kept hidden from most family members. Then, the person goes through a long trial of different treatments, many of which don't work.
Thankfully, that last step has been shortened by the advent of biologic drugs, said Dr. Alan Menter, a clinical professor of dermatology at the University of Texas Southwestern Medical School in Dallas and founder of the International Psoriasis Council.
Menter, who was interviewed for Finkelstein's film, said it accurately portrays the emotional burden of the disease.
For example, when patients first come to him for medical help, they often are overweight and depressed, Menter said. Most newly-diagnosed patients are young adults.
"For example, you take a 25-year-old, standing in the mirror seeing these crusted patches all over his or her body. They're trying to go out and get a date and it's crushing. They can hide it with clothing but that can't hide it from themselves or when they relationship starts becoming intimate," he said.
But Menter and Finkelstein are both optimistic that this will be less of a problem in the coming years, as more people are treated with medicines that truly help quell the disease.
"Right now I think there are something like 40 new drugs," Finkelstein said. "The future looks very bright for all of us who have suffered for so many years. I think it's a very good time to be talking about psoriasis."

Friday, October 21, 2005

What is Psoriasis?

Psoriasis is a common immune-mediated chronic skin disease that comes in different forms and varying levels of severity. Most researchers now conclude that it is related to the immune system (psoriasis is often called an "immune-mediated" disorder).It is not contagious. In general, it is a condition that is frequently found on the knees, elbows, scalp, hands, feet or lower back. Many treatments are available to help manage its symptoms. More than 4.5 million adults in the United States have it. Between 10 percent and 30 percent of people with psoriasis also develop a related form of arthritis, called psoriatic arthritis.

Thursday, October 20, 2005

Psoriasis and the T-Cell Connection

Scientists believe that certain white blood cells called T lymphocytes (T cells) play an important role in psoriasis. "And the disease has a genetic component," says Lindstrom. In about one-third of psoriasis cases, there is a family history of the disease.
T cells circulate throughout the body, orchestrating the immune system's response to foreign invaders like bacteria or viruses. In people with psoriasis, the defective T cells are overactive and migrate to the skin as if to heal a wound or ward off an infection. This process leads to the rapid growth of skin cells, triggering inflammation and the development of lesions.
Both the environment and genetics may play a role in the development of psoriasis. "In genetically predisposed children, psoriasis can be triggered by a strep or other infection," says Lindstrom. That's what happened to author John Updike. After an attack of measles at the age of 6, Updike developed psoriasis "in all its flaming scabbiness from head to toe," as he later described it in his memoir, Self-Consciousness.

Tuesday, October 18, 2005

PSORIASIS: CURE OR REMISSION

While the disease never goes away, the symptoms of psoriasis subside for a while (remission) and then return (flare-up, or reactivation). Remission can last for years in some people; in others, flare-ups occur every few weeks. Certain triggers, such as stress and seasonal changes, can reactivate psoriasis. "Certain drugs may also exacerbate it," says Lindstrom, including lithium, prescribed for bipolar disorder (also called manic-depressive illness), beta-blockers used to treat high blood pressure, and antimalarial drugs.

Saturday, October 15, 2005

Arthritis Drug Treats Psoriasis

A drug for rheumatoid arthritis can relieve the suffering of patients with moderate to severe psoriasis for a year, researchers said on Friday.
They found that infliximab, which is marketed under the name Remicade by Johnson & Johnson in the United States and by Schering-Plough Corp in other markets, improved symptoms of the chronic skin condition that affects 2 percent of the population in western countries.
"This is the first study to show that the very rapid and dramatic improvement that you see with psoriasis can, in the majority of patients, be maintained over at least the medium term -- over the course of a year," said Professor Christopher Griffiths, of the University of Manchester in England.
Previous trials have only looked into the impact of the drug on psoriasis over a short period of about 12 weeks.
The study published in The Lancet medical journal also showed patients saw a significant improvement in one of the most disturbing features of psoriasis: nail disease.
"Up until now it has been extremely difficult to treat," Griffiths told Reuters.
He and his colleagues compared the effects of the intravenous treatment to a placebo, or dummy drug, on 378 patients with the illness.
Each patient was given three intravenous infusions of the drug or a placebo over six weeks and then every 8 weeks for nearly a year. After less than 3 months on the treatment, 80 percent of the patients showed at least a 75 percent improvement, compared to 3 percent in the placebo group.
By the end of the trial, the drug completely cleared the skin condition in a quarter of patients but no one in the placebo group had the same result.
"Some of the patients were improved to the extent that they had no psoriasis and there was no impairment of their quality of life. So this is the best result you could possibly aim for with a treatment for psoriasis," said Griffiths.
"Compared with the other available treatments, it does work extremely effectively and extremely quickly."
The scientists said none of the patients given the drug had any serious side effects. But they stressed that the treatment is not a cure. It is likely patients would have to be on a long-term maintenance programme.
Psoriasis, an immune mediated disease, can develop at any age but it occurs most commonly before the age of 40. Psoriasis patches can also show up on the fingernails and toenails. About 15 percent of patients also suffer from arthritis linked to the condition.
European regulators recently approved infliximab for the treatment of psoriasis but the drug has not yet been approved for the skin condition in the United States.
The drug is also used as a treatment for Crohn's disease, an inflammatory bowel condition.

Thursday, October 13, 2005

TREATING PSORIASIS WITH LIGHT THERAPY

Exposing the skin to ultraviolet (UV) light--either from the sun or an artificial source--sets off a biological process that kills T cells, which slows the buildup of skin cells and reduces inflammation.
Light boxes that emit UV light to treat moderate-to-severe psoriasis and other skin diseases are medical devices that require licensing by the FDA. A person steps into the light box, which is about the size of a telephone booth, while lamps direct the light onto the body.
"Treatment with these devices is complex," says Richard Felten, an FDA chemist and senior medical device reviewer. The physician must determine an individual's sensitivity to UV and adjust the light emissions for the most effective treatment with the least risk of side effects, he says. Side effects may include burning, darkened skin, premature aging, and skin cancer. Three to five treatments per week for several weeks or months may be needed to get the psoriasis under control, followed by weekly maintenance treatments.
Light therapy, or phototherapy, is usually done in the physician's office or a medical facility that has the devices, says Felten. "The FDA has cleared some devices for home use under certain conditions and with a doctor's prescription," he says. Home devices include handheld devices for scalp psoriasis and stand-alone light boxes for other areas of the body.
Light therapy usually involves a short wavelength of ultraviolet light, called UVB. For people with resistant moderate-to-severe psoriasis, a combination of an oral or topical drug called psoralen and a longer wavelength ultraviolet A (UVA) light is used. This treatment is called "psoralen plus UVA" (PUVA).
"Psoralen makes the patient more sensitive to the UVA," says Lindstrom, "so once they've taken a dose of psoralen, a smaller dose of UVA is needed to treat them." Patients must be very careful to protect both skin and eyes for 24 hours after psoralen use to prevent damage, she says.
The FDA has also approved a special type of laser, an excimer laser, as a phototherapy device to treat mild-to-moderate psoriasis. "These lasers can deliver a much more controlled beam of light to small areas of the affected skin," says Felten.

Tuesday, October 11, 2005

Systemic Psoriasis Treatments

The FDA has approved oral and injected drugs that circulate throughout the body to treat psoriasis that is moderate, severe, or disabling. These systemic drugs are very powerful, and while some may be used continuously, others can only be used for a limited time because of their severe side effects. Once a drug is discontinued, the psoriasis may reactivate. The risk of birth defects prevents many systemics from being taken by pregnant women or women planning to become pregnant.
Systemic drugs that may be prescribed for psoriasis include acitretin, methotrexate, cyclosporine, and biologics, which are drugs made from proteins of living cells. Methotrexate, cyclosporine, and the biologic drugs are immunosuppressants, meaning they lower the body's normal immune response. "These drugs suppress the immune cells that cause psoriasis, but they don't distinguish these cells from the immune cells that protect our body from infections," says Elektra Papadopoulos, M.D., an FDA dermatologist.
Acitretin, a retinoid that is given orally for severe psoriasis, helps normalize the growth of skin cells. One of the side effects is raised fat (lipid) levels in the blood, and people taking this drug must get regular blood tests to monitor their cholesterol and triglyceride levels.
Methotrexate and cyclosporine slow the growth of skin cells. Methotrexate, taken orally or by injection, is also a chemotherapy drug for cancer patients. Cyclosporine, taken orally, was first approved to prevent organ rejection in transplant recipients. People using either of these drugs must be closely monitored and should use them only for short periods of time because of serious, potentially fatal, side effects.
Biologics are the newest systemic psoriasis treatments. Since 2003, the FDA has licensed three biologics to treat moderate-to-severe plaque psoriasis: Amevive (alefacept), manufactured by Biogen Inc.; Raptiva (efalizumab), made by Genentech Inc.; and Enbrel (etanercept), marketed by Amgen Inc. and Wyeth Pharmaceuticals. Enbrel was first licensed in 2002 to treat the arthritis associated with psoriasis, and in 2004 to treat psoriasis itself.
"All are immunosuppressive and have different proposed mechanisms," says Papadopoulos. Amevive simultaneously reduces the number of immune cells, including T cells, and inhibits T-cell activation. Raptiva inhibits the activation of T cells and the migration of those cells across blood vessels and into tissues, including the skin.
Enbrel inhibits the action of an inflammatory chemical messenger in the immune system called tumor necrosis factor-alpha (TNF-alpha), which is believed to play a role in both the skin and the joint symptoms of psoriasis.
All three biologics are injected. The FDA has licensed Amevive to be given in a physician's office, either injected into the muscle or into a vein (intravenously). It's a once-a-week treatment for 12 weeks; further treatments may be given after a waiting period.
The FDA has licensed Raptiva and Enbrel for home treatment. People can inject themselves with Raptiva under the skin once a week or with Enbrel once or twice a week. Both drugs are recommended for continuous use to maintain results.
Since biologic drugs are immunosuppressants, they may carry an increased risk of infection and cancer. Rare but serious effects have also included blood abnormalities and autoimmune diseases such as lupus. Other side effects are flu-like symptoms and pain and inflammation at the injection site.
Some dermatologists prescribe biologics alone for psoriasis or in combination with topical treatments. Leonardi says when he prescribes biologics, "I don't have to resort to adding other systemic therapies such as methotrexate, cyclosporine, acitretin, or phototherapy."
"Biologics are an alternative treatment to some of the traditional therapies," says Papadopoulos.
"Now we need to get the expense down," says Leonardi, who has patients who pay $30,000 per year on drugs to treat psoriasis.
Bird feels fortunate that her insurance company covers most of the expense of Enbrel, which is prescribed for both her psoriasis and psoriatic arthritis. Because of the arthritis pain, she has used a cane to help her walk and has had surgery on her wrist to correct some of the arthritis damage. Although Enbrel has been less effective over time for the psoriasis, she says, it's reduced her arthritic pain by about 95 percent. "I can jog down to the corner to chase after the dog," she says. "And last summer, I went hiking with my children in Colorado."

Saturday, October 08, 2005

Reducing Psoriasis Treatment Risks

Biologics, other systemic drugs, and phototherapy are powerful treatments with increased risks, says Lindstrom.
Biologics may raise the risk for developing cancer and serious bacterial or fungal infections that spread throughout the body (sepsis).
Cyclosporine can damage the kidneys, methotrexate puts the liver and lungs at risk, and phototherapy can cause skin cancer. To reduce these risks, doctors often put patients on "rotational therapy." "The thought is by moving from one therapy to another therapy over time, the risk to any individual organ is reduced," says Lindstrom.
"We also try to choose a drug with an appropriate benefit-risk ratio," she says. For mild psoriasis, a topical steroid may be appropriate. For more severe disease, where it becomes impractical to apply topicals over a large surface area several times a day, a patient may need a systemic treatment.
Most of the highly effective treatments for psoriasis affect the immune system in some way. For steroid drugs, which have been around for more than 50 years, the risks are well known. But less is known about the long-term side effects of newer drugs, such as the biologics. The safety and side effects of biologics and other immune-suppressing drugs to treat psoriasis continue to be monitored by drug manufacturers and the FDA

Thursday, October 06, 2005

The Future of Psoriasis Treatments

Researchers continue to look for reasons why immune cells overreact and what genes may be responsible for psoriasis, hoping to find better treatments, and eventually a cure. Psoriasis research is aided by the visibility of the symptoms on the skin.
"You can see the disease," says Leonardi. "You don't have to do invasive testing to see the effects of therapy." Psoriasis research has a "tremendous spillover into other fields besides dermatology," he adds. "There is a huge need for drugs to suppress the immune system without the side effects."
Multiple sclerosis, Crohn's disease, rheumatoid arthritis, and type 1 diabetes are just a few of the diseases that may also benefit from psoriasis research.

Monday, October 03, 2005

Finding the Right Treatment for Psoriasis

You may need to try different treatments before you find one that works well for you. It is important to discuss your treatment and progress with your doctor.
A recent study found that education, stress reduction, and muscle relaxation training can be beneficial to many people with psoriasis. Adding these elements to a treatment plan can reduce disability, anxiety, and stress related to dealing with psoriasis.
Treatments for psoriasis have potential side effects. People with moderate or severe psoriasis may need treatment for the rest of their lives. Many doctors will recommend that treatments be changed or rotated after a certain period of time to improve treatment effectiveness and reduce side effects.

Saturday, October 01, 2005

Treating Psoriasis: Amevive

AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a prescription medication that is injected by your doctor (15 mg IM, into the muscle) once a week, for a total of 12 doses.

Amevivie is not without side effects.
The most serious adverse reactions were:
Lymphopenia (see WARNINGS)
Malignancies (see WARNINGS)
Serious Infections requiring hospitalization (see WARNINGS)
Hypersensitivity Reactions (see PRECAUTIONS, Allergic Reactions)
Commonly observed adverse events seen in the first course of placebo-controlled clinical trials with at least a 2% higher incidence in the AMEVIVE®-treated patients compared to placebo-treated patients were: pharyngitis, dizziness, increased cough, nausea, pruritus, myalgia, chills, injection site pain, injection site inflammation, and accidental injury. The only adverse event that occurred at a 5% or higher incidence among AMEVIVE®-treated patients compared to placebo-treated patients was chills (1% placebo vs. 6% AMEVIVE®), which occurred predominantly with intravenous administration.